| Revenue TTM | ₹16,927 CrOperating Revenue |
|---|---|
| Market Cap | ₹69,376 CrMid-range Performer |
| PE TTM | 179.92Valuation Score 33 |
| Day RSI | 49.33Neutral Zone |
Key highlights
- Yesafili is the first interchangeable biosimilar to Regeneron's Eylea 2 mg approved by the FDA
- Target market includes approximately 20 million Americans living with age-related macular degeneration
- Reference product aflibercept recorded approximately 5.89 billion dollars in United States sales during 2023
- FDA interchangeable designation allows for substitution at the pharmacy level under state laws
- Product is indicated for Neovascular Wet AMD and Diabetic Macular Edema among other serious eye conditions
The Product — What It Is
Yesafili (aflibercept-jbvf) is a vascular endothelial growth factor inhibitor developed as a highly similar version of the reference product Eylea 2 mg. It is specifically designed to treat various ophthalmology conditions including Neovascular (Wet) Age-Related Macular Degeneration, Macular Edema following Retinal Vein Occlusion, Diabetic Macular Edema, and Diabetic Retinopathy. The product received its initial U.S.
Food and Drug Administration approval and an interchangeable designation in May 2024. This designation signifies that the biosimilar vial may be substituted for the reference product without the intervention of the prescribing healthcare provider, facilitating broader access to treatment for patients with serious eye conditions.
Commercial Opportunity
- The reference product Eylea 2 mg generated approximately 5.89 billion dollars in U.S. sales in 2023
- Approximately 19.8 million Americans are currently living with age-related macular degeneration
- Yesafili is positioned as one of the first interchangeable biosimilars to Eylea in the United States
- The interchangeable status allows for pharmacy-level substitution in accordance with specific state regulations
- The product addresses a significant health concern as AMD remains a leading cause of irreversible vision loss in adults over sixty
Strategic Fit
The launch of Yesafili represents a critical expansion of Biocon's global biosimilars portfolio, particularly within the ophthalmology segment. By entering the U.S. market with an interchangeable product, the company leverages its integrated lab-to-patient model to compete in high-value therapeutic areas.
This move aligns with Biocon’s broader strategy of providing affordable alternatives to complex biologic medicines. To date, the company has commercialized twelve biosimilar products and over thirty generic formulations across more than 120 countries, supported by seven manufacturing sites and a robust research and development pipeline containing more than twenty biosimilar assets.
Management Perspective
The launch of Yesafili in the U.S. marks an important step in expanding the global availability of biosimilar Aflibercept 2 mg for patients with eye conditions. This milestone further strengthens our presence in ophthalmology and builds on our FDA approval as one of the first interchangeable biosimilars to Eylea 2 mg, advancing access to life-changing medicines for patients around the world.
Business Overview
Biocon Limited is a global biopharmaceutical leader headquartered in Bengaluru, India, focusing on chronic and non-communicable diseases. The company operates through a diversified portfolio spanning diabetes, oncology, obesity, cardiovascular diseases, and immunology. With a workforce exceeding 9,500 employees, Biocon maintains a strong presence in international markets, evidenced by its inclusion in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year.
The company’s growth is driven by its ability to navigate complex regulatory landscapes and maintain a robust research and development engine, ensuring a reliable supply of biosimilars and generic medicines to meet global healthcare demands.
| Share price | ₹425.7 |
|---|---|
| Market capitalisation | ₹69,376.08 Cr |
| Revenue (annual) | ₹16,927.00 Cr |
| Net profit (annual) | ₹385.60 Cr |
| Revenue (latest quarter) | ₹4,516.60 Cr+8.23% vs previous quarter |
| Net profit (latest quarter) | ₹125.90 Cr-12.45% vs previous quarter |
| P/E (TTM) | 179.92×Sector 42.32× |
| Promoter holding | 44.68%-0.23% QoQ |
| FII holding | 8.14%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Biocon Limited announcing the commercial launch of Yesafili, a biosimilar to Eylea, in the United States market. Market figures from a third-party data provider.
